GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » Shiller PE Ratio

Assembly Biosciences (FRA:V7B) Shiller PE Ratio : (As of Jun. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Assembly Biosciences Shiller PE Ratio Historical Data

The historical data trend for Assembly Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Shiller PE Ratio Chart

Assembly Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Assembly Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Assembly Biosciences's Shiller PE Ratio

For the Biotechnology subindustry, Assembly Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Shiller PE Ratio falls into.



Assembly Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Assembly Biosciences's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Assembly Biosciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.527/131.7762*131.7762
=-1.527

Current CPI (Mar. 2024) = 131.7762.

Assembly Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -4.593 100.560 -6.019
201409 -12.385 100.428 -16.251
201412 -5.681 99.070 -7.557
201503 -7.096 99.621 -9.386
201506 -4.384 100.684 -5.738
201509 -4.063 100.392 -5.333
201512 -4.957 99.792 -6.546
201603 -6.897 100.470 -9.046
201606 -6.301 101.688 -8.165
201609 -7.164 101.861 -9.268
201612 -7.622 101.863 -9.860
201703 -9.088 102.862 -11.643
201706 -8.330 103.349 -10.621
201709 -7.148 104.136 -9.045
201712 -1.115 104.011 -1.413
201803 -7.786 105.290 -9.745
201806 -13.354 106.317 -16.552
201809 -8.947 106.507 -11.070
201812 -10.864 105.998 -13.506
201903 -11.151 107.251 -13.701
201906 -7.646 108.070 -9.323
201909 -10.460 108.329 -12.724
201912 -10.584 108.420 -12.864
202003 -8.254 108.902 -9.988
202006 2.025 108.767 2.453
202009 -0.917 109.815 -1.100
202012 -10.949 109.897 -13.129
202103 -6.955 111.754 -8.201
202106 -5.478 114.631 -6.297
202109 -4.182 115.734 -4.762
202112 -14.549 117.630 -16.299
202203 -5.230 121.301 -5.682
202206 -5.790 125.017 -6.103
202209 -5.818 125.227 -6.122
202212 -5.249 125.222 -5.524
202303 -4.166 127.348 -4.311
202306 -3.544 128.729 -3.628
202309 -3.036 129.860 -3.081
202312 -1.596 129.419 -1.625
202403 -1.527 131.776 -1.527

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Assembly Biosciences  (FRA:V7B) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Assembly Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Assembly Biosciences (FRA:V7B) Business Description

Traded in Other Exchanges
Address
331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences (FRA:V7B) Headlines

No Headlines